MORC2: A Potential Drug Target Or Biomarker (G22880)

Target Name: MORC2

NCBI ID: G22880

MORC2

MORC2: A Potential Drug Target Or Biomarker

MORC2, or MORC family CW-type zinc finger protein 2, is a protein that is expressed in various tissues throughout the body. It is a key regulator of gene expression and has been implicated in a number of cellular processes, including cell growth, differentiation, and metabolism. In recent years, researchers have become increasingly interested in MORC2 as a potential drug target or biomarker.

The MORC2 protein is composed of 254 amino acid residues and has a calculated molecular mass of 31.1 kDa. It is expressed in a variety of tissues, including muscle, heart, kidney, liver, and brain. It is also highly expressed in placenta, suggesting that it may be involved in fetal development and growth. MORC2 is a member of the MORC family of zinc finger proteins, which are a group of non-coding RNAs that play important roles in gene regulation.

MORC2 has been shown to play a role in a number of cellular processes. For example, it has been shown to regulate the expression of genes involved in cell growth, differentiation, and metabolism. It has also been shown to play a role in cell-cell signaling, as well as in cell-tissue signaling. In addition, MORC2 has been shown to play a role in the regulation of stem cell self-renewal and proliferation.

In recent years, researchers have been exploring the potential uses of MORC2 as a drug target or biomarker. One approach is to use small molecules to disrupt the activity of MORC2, with the goal of inhibiting its ability to regulate gene expression. This approach has been successful in animal models of cancer, with researchers reporting that treatment with small molecules that disrupt MORC2 activity can lead to significant reductions in cancer cell proliferation.

Another approach to using MORC2 as a drug target or biomarker is to use antibodies to target MORC2 specifically. This approach has been shown to be effective in human studies, with researchers reporting that targeting MORC2 with antibodies can lead to significant reductions in MORC2-expressing cell proliferation.

In addition to its potential as a drug target or biomarker, MORC2 has also been shown to be a potential biomarker for a number of diseases. For example, MORC2 has been shown to be expressed in a variety of cancer types, including breast, ovarian, and colorectal cancers. It has also been shown to be expressed in the placenta, which suggests that it may be involved in the development and progression of these cancers. In addition, MORC2 has been shown to be involved in the regulation of fetal development and growth, which suggests that it may be involved in the development of certain diseases.

Overall, MORC2 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in cellular processes and its potential as a therapeutic agent.

Protein Name: MORC Family CW-type Zinc Finger 2

Functions: Essential for epigenetic silencing by the HUSH (human silencing hub) complex. Recruited by HUSH to target site in heterochromatin, the ATPase activity and homodimerization are critical for HUSH-mediated silencing (PubMed:28581500, PubMed:29440755, PubMed:32693025). Represses germ cell-related genes and L1 retrotransposons in collaboration with SETDB1 and the HUSH complex, the silencing is dependent of repressive epigenetic modifications, such as H3K9me3 mark. Silencing events often occur within introns of transcriptionally active genes, and lead to the down-regulation of host gene expression (PubMed:29211708). During DNA damage response, regulates chromatin remodeling through ATP hydrolysis. Upon DNA damage, is phosphorylated by PAK1, both colocalize to chromatin and induce H2AX expression. ATPase activity is required and dependent of phosphorylation by PAK1 and presence of DNA (PubMed:23260667). Recruits histone deacetylases, such as HDAC4, to promoter regions, causing local histone H3 deacetylation and transcriptional repression of genes such as CA9 (PubMed:20225202, PubMed:20110259). Exhibits a cytosolic function in lipogenesis, adipogenic differentiation, and lipid homeostasis by increasing the activity of ACLY, possibly preventing its dephosphorylation (PubMed:24286864)

The "MORC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MORC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets